By Cannibalizing Nearby Stromal Stem Cells, Some Breast Cancer Cells Gain Invasion Advantage

Cancer biologists and engineers collaborated on a device that could help predict the likelihood of breast cancer metastasis.

11:00 AM

Author | Ian Demsky

It's a you-are-what-you-eat story starring breast cancer cells.

Researchers at the University of Michigan Rogel Cancer Center and U-M College of Engineering have found that breast cancer cells that swallow up nearby stem cells take on some of their properties, enhancing their ability to invade other tissues throughout the body and seed secondary tumors, a process known as metastasis.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

There's a clinical need to better understand the metastatic process and how metastasis is influenced by the environment of cells around a tumor.
Celina Kleer, M.D.

It started with an unexpected observation in the lab, and led to the development of a microfluidic device that researchers hope might help predict the likelihood that a breast cancer patient's disease will spread.

The team's findings appear in the journal Cell Reports.

"There's a clinical need to better understand the metastatic process and how metastasis is influenced by the microenvironment of cells around a tumor. There is very little known on these kinds of interactions between cells," says study senior author Celina Kleer, M.D., professor of pathology at Michigan Medicine and director of U-M's breast pathology program. "About 20% of breast cancer patients develop distant metastases, for which there is no cure."

An intriguing observation

A few years ago, during an analysis of cells from breast cancer patients whose cancer had metastasized, Maria Gonzalez, M.S., a senior researcher in the Kleer lab and one of the study's lead authors, discovered a population of cancer cells that had evidence of other cells inside them. 

"The way it started was really interesting," Kleer says. "We isolated mesenchymal stem cells and cultured them together with breast cancer cells to see what properties were induced or inhibited.

"And when we did flow cytometry, we consistently found that there was this small population of cells that had features of both types of cells," she says.

SEE ALSO: How Targeting Metabolism Can Defeat Cancer Stem Cells

The mesenchymal stem cells had been labeled to glow red and the breast cancer cells made to fluoresce green.

"We were surprised to see a hybrid cell population that turned yellow and decided to investigate the biology behind this experimental observation," she says.

Biologists and engineers team up

This led to further experiments to study what was happening in detail and how it affected the cancer cells' aggressiveness.

The cancer researchers teamed up with scientists from the U-M College of Engineering — including research scientist Yu-Chih Chen, Ph.D., the other lead author of the study, and Euisik Yoon, Ph.D., professor of electrical engineering and computer science and of biomedical engineering — to develop a microfluidic device, sometimes called a lab-on-a-chip, that would allow them to isolate and study the hybrid cells.

The device allowed researchers to pair a single breast cancer cell and a single mesenchymal-stem cell, and directly observe the engulfment process. The approach also allowed for the selective isolation of cells for additional analysis, Chen says.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Research showed these mesenchymal-stem-cell-eating cancer cells developed significant changes in the genes they expressed, including several known to be involved in metastasis, Kleer notes. And in mouse models, the hybrid cells led to much more extensive metastasis than non-cell-engulfing control cells.

"These findings reveal how the direct interaction of cancer cells with mesenchymal stem cells can lead to the development of aggressive cancer," Kleer says.

"Not only does this open up new avenues to study the underlying biological mechanisms, but the microfluidic chip and method we've developed could be the starting point for a clinical test to help determine the likelihood that a breast cancer patient's tumor will metastasize," she says.

U-M has filed for patent protection on the microfluidic device.

 


More Articles About: Lab Report Breast cancer Cancer Research Cancer Diagnosis Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories frozen dial with ice on it with red dial
Health Lab
Enzyme identified as new therapeutic target for “cold” tumors
A study identifies an enzyme as a new therapeutic target for “cold” tumors.
three friends standing outside rogel cancer center building with big white ribbons
Health Lab
A lung cancer survivor shaping lung cancer advocacy
One woman's unexpected lung cancer diagnosis leads her to help many who aren't aware they're at risk of the disease.
close up of orange and purple squiggle-looking cells merging and a little green in the middle
Health Lab
Researchers find metabolic mechanism that blocks immune response, immunotherapy in cancer
New research has discovered why some cancers don’t respond to immunotherapy treatment: A metabolite transporter within the tumor microenvironment blocks a key type of tumor cell death integral to immune response.
graphic drawing of woman falling and everything is pink and falling and floating with her like dna strands, cars, people, medicine, ID, blood vessels and cells
Health Lab
Why are more young people being diagnosed with cancer?
An article discusses causes of early-onset cancer and ways to reduce your risk.
doctors talking to eachother down a hallway
Health Lab
A collaborative approach to pancreatic cancer
The Rogel and Blondy Center for Pancreatic Cancer is a center of excellence in pancreatic cancer research, combining pioneering research with innovative clinical care and an array of clinical trials. Center co-director Marina Pasca di Magliano explains that the key to a robust research program and responsive care lies in collaboration.
Susan and Richard Rogel pose next to a grand piano. Rogel is wearing a polo shirt with a block M.
News Release
Rogel Cancer Center receives $50M gift to revolutionize pancreatic cancer care, research
New Rogel and Blondy Center for Pancreatic Cancer will bring together researchers and clinicians to drive forward new treatments and improve outcomes